Cartalax

Compound Overview

Research Use Only. Not for Human Consumption.

Cartalax is supplied by Nexus as a sequence-defined short peptide bioregulator for controlled in-vitro research and analytical workflows. The sourced chemistry record identifies Cartalax as Ala-Glu-Asp, abbreviated AED, a 3-residue synthetic peptide associated with cartilage and connective-tissue research models.

Cartalax is categorized in the Nexus catalog under Russian Bioregulators. The current Nexus variant is a 20mg research-size vial under SKU LAX20. The available source record supports its peptide sequence, classification, molecular formula, calculated molecular weight, physical form, intended use, and storage guidance. It does not provide a confirmed CAS number, lot-specific purity value, salt or counter-ion assignment, batch number, or Certificate of Analysis values.

Because the current product record is intentionally limited, this description is limited as well. It does not infer therapeutic properties, dosing information, biological outcomes, mechanism-specific findings, or compound-specific handling details beyond the facts included in the research record.

• Product: Cartalax
• SKU: LAX20
• Available Research Size: 20mg
• Class: Khavinson short peptide bioregulator
• Sequence: AED
• Sequence Display: Ala-Glu-Asp
• Physical Form: Lyophilized powder
• Use: For in-vitro research use only. Not for human consumption.

Research Background & Published Literature

The available literature for Cartalax is concentrated in Russian and Eastern European bioregulator research. For this product record, the strongest usable chemistry anchor is the defined amino-acid sequence: Ala-Glu-Asp. That sequence provides the basis for the calculated molecular formula and molecular weight listed in the technical specifications below.

Cartalax is identified in the supplied research data as a Khavinson short peptide bioregulator associated with cartilage and connective-tissue research models. The provided record does not include detailed experimental abstracts, validated mechanism-specific findings, in-vitro assay conditions, or lot-level release analytics. For that reason, this page avoids unsupported statements about biological effects and treats the AED sequence, classification, physical form, and computed chemistry values as the primary verified descriptors.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Lin'kova et al. (2011) — Bull Exp Biol Med
• Chalisova et al. (2015) — Bull Exp Biol Med
• Lin'kova et al. (2016) — Bull Exp Biol Med

Storage, Handling & Stability Guidelines

Store lyophilized Cartalax material at -20°C, desiccated, and protected from light. These are the only Cartalax-specific storage parameters included in the current research record.

Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.

Laboratories should document handling conditions according to their own validated internal procedures and preserve traceability between aliquots, source vial, and lot-level verification records. The absence of a provided stability study means this description should be treated as a conservative storage summary rather than a complete stability protocol.

Quality Assurance & Lab Verification

The Certificate of Analysis for this catalog item is pending. No provisional batch, assay, method, analyst, or release data is published in this product dossier. Check the Lab Verified archive for documentation status.